# Lyell Immunopharma **Source:** https://geo.sig.ai/brands/lyell-immunopharma **Vertical:** Biotechnology **Subcategory:** Cell Therapy **Tier:** Emerging **Website:** lyell.com **Last Updated:** 2026-04-14 ## Summary Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell therapy. ## Company Overview Lyell Immunopharma is a clinical-stage cell therapy company founded in 2018 by Rick Klausner and publicly traded on Nasdaq. The company focuses on next-generation CAR-T therapies that address the key limitations of first-generation products, particularly the exhaustion and dysfunction of engineered T cells that limits efficacy especially against solid tumors. Lyell has developed proprietary T cell reprogramming technologies including gene overexpression approaches that maintain T cell stemness and fitness during manufacturing and after infusion. The company is applying these technologies to both hematological malignancies and solid tumors in a pipeline of clinical programs. Lyell has established a research collaboration with GlaxoSmithKline to combine cell therapy expertise. While first-generation CAR-T products have demonstrated remarkable responses in blood cancers, Lyell is focused on the much larger unmet need in solid tumors where current CAR-T therapies have shown limited efficacy. The company represents the scientific evolution of the cell therapy field toward more durable and broadly applicable treatments. ## Frequently Asked Questions ### What is Lyell Immunopharma? Lyell Immunopharma develops next-generation CAR-T cell therapies using proprietary T cell reprogramming technologies designed to overcome exhaustion and extend efficacy, especially in solid tumors where current therapies struggle. ### What problem does Lyell address in CAR-T therapy? First-generation CAR-T cells often become exhausted and dysfunctional after infusion, limiting their ability to eliminate tumor cells especially in solid tumors. Lyell's technologies aim to maintain T cell fitness and stemness for more durable anti-tumor responses. ### Is Lyell publicly traded? Yes, Lyell Immunopharma trades on Nasdaq under the ticker LYEL and is a clinical-stage company advancing a pipeline of engineered T cell therapies for both blood cancers and solid tumors. ### What is CAR-T cell exhaustion and how does Lyell address it? CAR-T cell exhaustion occurs when engineered immune cells lose their cancer-killing function after sustained activation in the tumor microenvironment — a major reason CAR-T therapies succeed in blood cancers but often fail in solid tumors. Lyell's technologies reprogram T cells to resist exhaustion, maintaining their anti-tumor activity for longer periods. ### What are Lyell's key T cell reprogramming technologies? Lyell's pipeline includes genetic reprogramming approaches that prevent T cells from entering exhaustion states, manufacturing improvements that produce younger, more potent T cells, and metabolic conditioning methods that improve T cell function in the immunosuppressive tumor microenvironment characteristic of solid tumors. ### What therapeutic areas is Lyell targeting? Lyell focuses on solid tumor oncology — the frontier where CAR-T therapy has historically underperformed. Target cancers include lung cancer, colorectal cancer, and other solid malignancies. Success here would represent a major expansion of the CAR-T market beyond current blood cancer indications. ### How much has Lyell Immunopharma raised and who are its investors? Lyell raised over $900M before going public on NASDAQ under the ticker LYEL in 2021. Investors include GlaxoSmithKline (which provided manufacturing and development support), SoftBank, and major biotech investors. GSK's involvement as both investor and partner reflects the pharmaceutical industry's interest in Lyell's platform. ### What is the current clinical stage of Lyell's programs? Lyell has multiple programs in Phase 1 clinical trials, testing its reprogrammed CAR-T therapies in solid tumor patients who have exhausted other treatment options. The company is generating early clinical data to demonstrate that its T cell reprogramming approach translates from preclinical models to human patients. ### What is Lyell's proprietary T cell reprogramming technology? Lyell uses epigenetic reprogramming techniques including c-Jun overexpression and nuclear receptor NR4A knockout to maintain T cell stemness and prevent exhaustion, creating CAR-T cells designed for durable anti-tumor activity. ### How much has Lyell raised? Lyell raised approximately $497 million in its 2021 Nasdaq IPO and has raised over $700 million in total, providing a strong balance sheet for advancing its clinical pipeline. ### What solid tumor programs is Lyell advancing? Lyell is advancing CAR-T programs targeting solid tumors including those expressing EGFRvIII and other surface antigens, addressing indications where current cell therapies have limited efficacy. ### Who are Lyell's scientific founders? Lyell was founded with strategic involvement from Carl June at Penn Medicine, a pioneer in CAR-T cell therapy, and has built a scientific advisory board of leaders in T cell biology and cancer immunology. ### What is the commercial challenge for Lyell compared to approved CAR-T companies? Lyell must demonstrate superior durability and solid tumor efficacy over approved CAR-T therapies like Kymriah and Yescarta to justify adoption, requiring compelling clinical trial data before commercial launch. ## Tags startup, technology, healthtech, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*